Home/Pipeline/ImmiPrint® Platform Pipeline

ImmiPrint® Platform Pipeline

Multiple Infectious, Autoimmune, Inflammatory Diseases

Early DiscoveryActive

Key Facts

Indication
Multiple Infectious, Autoimmune, Inflammatory Diseases
Phase
Early Discovery
Status
Active
Company

About ProteinLogic

Founded in 2004 and based in Cambridge, UK, ProteinLogic is a private diagnostics company pioneering a novel approach to disease detection and monitoring. Its core ImmiPrint® platform analyzes patterns of soluble Cluster of Differentiation (sCD) antigens using high-throughput immunoassays and machine learning to generate disease-specific diagnostic signatures. The company has clinically validated its first signature for Active Tuberculosis and holds an early-stage pipeline targeting infectious, autoimmune, and inflammatory diseases, positioning it in the growing field of precision diagnostics.

View full company profile